FDA chief scientist wants BPA review
This article was originally published in The Tan Sheet
Executive Summary
At the request of newly appointed FDA Chief Scientist Frank M. Torti, a new Science Board subcommittee will hold a public meeting on the safety of bisphenol-A in plastics, review an FDA Task Force report on BPA and deliver its findings to the Science Board's annual meeting in the fall, according to a June 6 FDA release. The Task Force will make recommendations to Commissioner Andrew von Eschenbach following its review. Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Oversight and Investigations Subcommittee Chairman Bart Stupak in April asked FDA to reconsider BPA's safety in infant products (1"The Tan Sheet" April 12, 2008, In Brief)...
You may also be interested in...
FDA releases BPA report
FDA releases the draft report on the safety of bisphenol-A in plastics related to food contact applications on Aug. 15, ahead of the Sept. 16 meeting of the BPA subcommittee of FDA's science board. The BPA subcommittee will meet at the Hilton Washington in Rockville, Md., to discuss the draft assessment of BPA for use in food contact applications, according to a same-day Federal Register notice. The subcommittee will also hear oral presentations from members of the public, the notice says. Chief Scientific Officer Frank Torti requested the BPA subcommittee's meeting and discussion of the FDA Task Force BPA report in early June (1"The Tan Sheet" June 9, 2008, In Brief)...
Bisphenol A safe?
Results of National Toxicology Program research prompt Michigan Democrats John Dingell, chairman of the House Energy and Commerce Committee, and Bart Stupak, Oversight and Investigations Subcommittee, to ask FDA to reconsider the safety of the chemical bisphenol A in products intended for use by infants and children. In an April 14 draft brief, the NTP concludes there is "some concern for neural and behavioral effects in fetuses, infants, and children at current human exposures" and "the possibility that bisphenol A may alter human development cannot be dismissed." Stupak says FDA relied on two industry-funded studies to determine the chemical's safety while other authorities "used all available data to reach vastly different conclusions"...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.